|
1
|
Ando K, Heymann MF, Stresing V, Mori K,
Rédini F and Heymann D: Current therapeutic strategies and novel
approaches in osteosarcoma. Cancers. 5:591–616. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Perry JA, Kiezun A, Tonzi P, Van Allen EM,
Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS,
et al: Complementary genomic approaches highlight the PI3K/mTOR
pathway as a common vulnerability in osteosarcoma. Proc Natl Acad
Sci USA. 111:pp. E5564–E5573. 2014; View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maugg D, Rothenaigner I, Schorpp K,
Potukuchi HK, Korsching E, Baumhoer D, Hadian K, Smida J and
Nathrath M: New small molecules targeting apoptosis and cell
viability in osteosarcoma. PLoS One. 10:e01290582015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tomsig JL and Creutz CE: Copines: A
ubiquitous family of Ca(2+)-dependent phospholipid-binding
proteins. Cell Mol Life Sci. 59:1467–1477. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maitra R, Grigoryev DN, Bera TK, Pastan IH
and Lee B: Cloning, molecular characterization, and expression
analysis of Copine 8. Biochem Biophys Res Commun. 303:842–847.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Creutz CE, Tomsig JL, Snyder SL, Gautier
MC, Skouri F, Beisson J and Cohen J: The copines, a novel class of
C2 domain-containing, calcium-dependent, phospholipid-binding
proteins conserved from Paramecium to humans. J Biol Chem.
273:1393–1402. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perestenko PV, Pooler AM, Noorbakhshnia M,
Gray A, Bauccio C and Jeffrey McIlhinney RA: Copines-1, −2, −3, −6
and −7 show different calcium-dependent intracellular membrane
translocation and targeting. FEBS J. 277:5174–5189. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tomsig JL, Snyder SL and Creutz CE:
Identification of targets for calcium signaling through the copine
family of proteins. Characterization of a coiled-coil
copine-binding motif. J Biol Chem. 278:10048–10054. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tomsig JL, Sohma H and Creutz CE:
Calcium-dependent regulation of tumour necrosis factor-alpha
receptor signalling by copine. Biochem J. 378:1089–1094. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hwang LH: Gene therapy strategies for
hepatocellular carcinoma. J Biomed Sci. 13:453–468. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Follenzi A and Gupta S: The promise of
lentiviral gene therapy for liver cancer. J Hepatol. 40:337–340.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zielske SP and Stevenson M: Importin 7 may
be dispensable for human immunodeficiency virus type 1 and simian
immunodeficiency virus infection of primary macrophages. J Virol.
79:11541–11546. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rocks O, Peyker A and Bastiaens PI:
Spatio-temporal segregation of Ras signals: One ship, three
anchors, many harbors. Curr Opin Cell Biol. 18:351–357. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Campbell SL, Khosravi-Far R, Rossman KL,
Clark GJ and Der CJ: Increasing complexity of Ras signaling.
Oncogene. 17(11 Reviews): 1–1413. 1998.PubMed/NCBI
|
|
15
|
Prior IA, Lewis PD and Mattos C: A
comprehensive survey of Ras mutations in cancer. Cancer Res.
72:2457–2467. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim W, Kim M and Jho EH: Wnt/β-catenin
signalling: From plasma membrane to nucleus. Biochem J. 450:9–21.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sasaya K, Sudo H, Maeda G, Kawashiri S and
Imai K: Concomitant loss of p120-catenin and β-catenin membrane
expression and oral carcinoma progression with E-cadherin
reduction. PLoS One. 8:e697772013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He TC, Sparks AB, Rago C, Hermeking H,
Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW:
Identification of c-MYC as a target of the APC pathway. Science.
281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tetsu O and McCormick F: Beta-catenin
regulates expression of cyclin D1 in colon carcinoma cells. Nature.
398:422–426. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arsenic R, Braicu EI, Letsch A, Dietel M,
Sehouli J, Keilholz U and Ochsenreither S: Cancer-testis antigen
cyclin A1 is broadly expressed in ovarian cancer and is associated
with prolonged time to tumor progression after platinum-based
therapy. BMC Cancer. 15:7842015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shames DS, Girard L, Gao B, Sato M, Lewis
CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, et al: A
genome-wide screen for promoter methylation in lung cancer
identifies novel methylation markers for multiple malignancies.
PLoS Med. 3:e4862006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Syed Khaja AS, Dizeyi N, Kopparapu PK,
Anagnostaki L, Härkönen P and Persson JL: Cyclin A1 modulates the
expression of vascular endothelial growth factor and promotes
hormone-dependent growth and angiogenesis of breast cancer. PLoS
One. 8:e722102013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wegiel B, Bjartell A, Ekberg J, Gadaleanu
V, Brunhoff C and Persson JL: A role for cyclin A1 in mediating the
autocrine expression of vascular endothelial growth factor in
prostate cancer. Oncogene. 24:6385–6393. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ji P, Agrawal S, Diederichs S, Bäumer N,
Becker A, Cauvet T, Kowski S, Beger C, Welte K, Berdel WE, et al:
Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell
cycle progression in somatic cells. Oncogene. 24:2739–2744. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim J, Kim WJ, Liu Z, Loda M and Freeman
MR: The ubiquitin-specific protease USP2a enhances tumor
progression by targeting cyclin A1 in bladder cancer. Cell Cycle.
11:1123–1130. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marlow LA, von Roemeling CA, Cooper SJ,
Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV, Tun
HW, et al: Foxo3a drives proliferation in anaplastic thyroid
carcinoma through transcriptional regulation of cyclin A1: A
paradigm shift that impacts current therapeutic strategies. J Cell
Sci. 125:4253–4263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wegiel B, Bjartell A, Culig Z and Persson
JL: Interleukin-6 activates PI3K/Akt pathway and regulates cyclin
A1 to promote prostate cancer cell survival. Int J Cancer.
122:1521–1529. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hoeller D and Dikic I: Targeting the
ubiquitin system in cancer therapy. Nature. 458:438–444. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vucic D, Dixit VM and Wertz IE:
Ubiquitylation in apoptosis: A post-translational modification at
the edge of life and death. Nat Rev Mol Cell Biol. 12:439–452.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vandenabeele P and Bertrand MJ: The role
of the IAP E3 ubiquitin ligases in regulating pattern-recognition
receptor signalling. Nat Rev Immunol. 12:833–844. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rhyasen GW and Starczynowski DT: IRAK
signalling in cancer. Br J Cancer. 112:232–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lin SC, Lo YC and Wu H: Helical assembly
in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature.
465:885–890. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kawagoe T, Sato S, Matsushita K, Kato H,
Matsui K, Kumagai Y, Saitoh T, Kawai T, Takeuchi O and Akira S:
Sequential control of Toll-like receptor-dependent responses by
IRAK1 and IRAK2. Nat Immunol. 9:684–691. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Teng ZY, Cheng XL, Cai XT, Yang Y, Sun XY,
Xu JD, Lu WG, Chen J, Hu CP, Zhou Q, et al: Ancient Chinese formula
Qiong-Yu-Gao protects against cisplatin-induced nephrotoxicity
without reducing anti-tumor activity. Sci Rep. 5:155922015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee K, Qian DZ, Rey S, Wei H, Liu JO and
Semenza GL: Anthracycline chemotherapy inhibits HIF-1
transcriptional activity and tumor-induced mobilization of
circulating angiogenic cells. Proc Natl Acad Sci USA. 106:pp.
2353–2358. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mizutani H, Tada-Oikawa S, Hiraku Y,
Kojima M and Kawanishi S: Mechanism of apoptosis induced by
doxorubicin through the generation of hydrogen peroxide. Life Sci.
76:1439–1453. 2005. View Article : Google Scholar : PubMed/NCBI
|
